Table 2. Results from models for the primary endpoint (severe or moderate dengue).
| Single models | Global model | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Children OR (95% CI) |
Adults OR (95% CI) |
Poverall | Pinteraction | Children OR (95% CI) |
Adults OR (95% CI) |
Poverall | Pinteraction | ||
| VCAM-1 (ng/ml) | <0.001 | 0.715 | 0.441 | 0.213 | |||||
| - 1636 vs 818 | 1.20 (1.04–1.38) | 1.35 (1.15–1.58) | 0.90 (0.73–1.10) | 1.22 (0.96–1.57) | |||||
| - 3272 vs 1636 | 1.25 (1.02–1.53) | 1.48 (1.19–1.85) | 0.87 (0.66–1.15) | 1.30 (0.93–1.80) | |||||
| SDC-1 (pg/ml) | <0.001 | 0.088 | 0.002 | 0.588 | |||||
| - 2519 vs 1260 | 2.67 (1.31–5.43) | 3.33 (1.32–8.42) | 2.03 (0.77–5.34) | 5.11 (1.56–16.78) | |||||
| - 5039 vs 2519 | 1.71 (1.18–2.47) | 3.71 (2.09–6.58) | 1.76 (0.98–3.14) | 2.52 (1.17–5.42) | |||||
| Ang-2 (pg/ml) | <0.001 | 0.524 | 0.039 | 0.068 | |||||
| - 1204 vs 602 | 1.64 (1.39–1.94) | 1.51 (1.26–1.82) | 1.67 (1.23–2.25) | 1.01 (0.74–1.38) | |||||
| - 2409 vs 1204 | 2.21 (1.58–3.10) | 2.00 (1.40–2.85) | 1.95 (1.25–3.05) | 1.01 (0.65–1.57) | |||||
| IL-8 (pg/ml) | <0.001 | <0.001 | <0.001 | <0.001 | |||||
| - 14 vs 7 | 1.42 (1.05–1.91) | 2.18 (1.47–3.24) | 0.91 (0.63–1.34) | 1.69 (1.05–2.71) | |||||
| - 28 vs 14 | 0.99 (0.78–1.25) | 2.33 (1.63–3.33) | 0.53 (0.36–0.77) | 2.05 (1.34–3.13) | |||||
| IP-10 (pg/ml) | <0.001 | 0.984 | 0.206 | 0.630 | |||||
| - 3093 vs 1546 | 1.46 (1.26–1.68) | 1.45 (1.21–1.73) | 0.94 (0.73–1.19) | 0.80 (0.57–1.12) | |||||
| - 6186 vs 3093 | 1.68 (1.35–2.09) | 1.69 (1.29–2.22) | 1.08 (0.77–1.51) | 0.82 (0.52–1.29) | |||||
| IL-1RA (pg/ml) | <0.001 | 0.082 | <0.001 | 0.032 | |||||
| - 6434 vs 3217 | 1.69 (1.42–2.03) | 1.48 (1.21–1.81) | 2.07 (1.52–2.84) | 1.45 (0.98–2.15) | |||||
| - 12868 vs 6434 | 1.82 (1.46–2.27) | 1.70 (1.29–2.24) | 2.16 (1.53–3.05) | 1.47 (0.94–2.30) | |||||
| sCD163 (ng/ml) | <0.001 | 0.551 | 0.217 | 0.341 | |||||
| - 295 vs 147 | 1.57 (1.14–2.15) | 1.49 (1.13–1.98) | 1.40 (0.89–2.22) | 1.27 (0.84–1.91) | |||||
| - 589 vs 295 | 1.46 (1.10–1.93) | 1.61 (1.09–2.37) | 1.21 (0.87–1.69) | 1.39 (0.89–2.18) | |||||
| sTREM-1 (pg/ml) | 0.059 | 0.997 | 0.555 | 0.393 | |||||
| - 85 vs 42 | 1.87 (1.23–2.84) | 1.79 (1.10–2.93) | 1.13 (0.70–1.81) | 1.21 (0.65–2.26) | |||||
| - 169 vs 85 | 1.12 (0.91–1.38) | 1.12 (0.82–1.53) | 0.89 (0.65–1.21) | 0.61 (0.38–0.99) | |||||
| Ferritin (ng/ml) | 0.042 | 0.054 | 0.008 | 0.002 | |||||
| - 243 vs 122 | 1.18 (1.01–1.38) | 1.06 (0.89–1.27) | 1.30 (1.04–1.64) | 0.78 (0.61–0.99) | |||||
| - 487 vs 243 | 1.26 (1.00–1.58) | 0.90 (0.66–1.23) | 1.22 (0.89–1.67) | 0.66 (0.44–1.00) | |||||
| CRP (mg/l) | <0.001 | 0.031 | 0.184 | 0.138 | |||||
| - 28 vs 14 | 1.26 (1.12–1.41) | 1.25 (1.03–1.52) | 1.08 (0.93–1.25) | 1.10 (0.85–1.44) | |||||
| - 56 vs 28 | 1.13 (0.95–1.34) | 1.38 (1.11–1.71) | 0.93 (0.75–1.15) | 1.36 (1.02–1.81) |
Poverall is derived from Wald test for the overall association of the biomarker with the endpoint; Pinteraction is from the test for the interaction between the biomarker and age. The odds ratios are estimated at age of 10 and 25 years, represented as children and adults respectively.